Name
GS3-06 - Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. (China)
Date & Time
Friday, December 20, 2024
Speakers
Virtual Session Link